CIK 0000200406
- Large accelerated filer
JOHNSON & JOHNSON
Sign in to watch- Ticker
- JNJ
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Jan 3
- Incorporated
- NJ
- Entity type
- Operating
- EIN
- 221024240
- Phone
- +1 732-524-2455
- Business address
- ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ, 08933
- Former names
- JOHNSON & JOHNSON ET AL
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,947,986
- in 2 filings
Net −$12,947,986. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-10 | HEWSON MARILLYN A Director | Grant or award · Deferred Share Units | +302.55 | $165.94 | $50K | 10,954.94 |
| 2024-08-30 | Decker Robert J VP Corporate Controller | Option exercise | +5,635 | $100.06 | $564K | 24,608 |
| 2024-08-30 | Decker Robert J VP Corporate Controller | Sale | −5,635 | $165.06 | $930K | 18,973 |
| 2024-08-30 | Decker Robert J VP Corporate Controller | Option exercise · Employee Stock Options (Right to Buy) | −5,635 | 0 | ||
| 2024-07-08 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise | +9,809 | 24,852 | ||
| 2024-07-08 | Broadhurst Vanessa EVP, Global Corp Affairs | Shares withheld for taxes | −5,018 | $147.16 | $738K | 19,834 |
| 2024-07-08 | Broadhurst Vanessa EVP, Global Corp Affairs | Option exercise · Restricted Share Units | −9,809 | 0 | ||
| 2024-06-04 | Woods Eugene A. Director | Grant or award · Deferred Share Units | +211.36 | $147.85 | $31K | 2,368.45 |
| 2024-06-04 | HEWSON MARILLYN A Director | Grant or award · Deferred Share Units | +314.62 | $147.85 | $47K | 10,573.38 |
| 2024-05-22 | Wolk Joseph J Exec VP, CFO | Gift | −55 | 68,835 | ||
| 2024-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | +25,255 | 25,561 | ||
| 2024-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Shares withheld for taxes | −10,984 | $144.59 | $1.6M | 14,577 |
| 2024-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise · Restricted Share Units | −25,255 | 50,510 | ||
| 2024-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise | +22,255 | 22,561 | ||
| 2024-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Shares withheld for taxes | −10,984 | $144.59 | $1.6M | 11,577 |
| 2024-05-01 | REED JOHN C EVP, Innovative Medicine, R&D | Option exercise · Restricted Share Units | −22,255 | 53,510 | ||
| 2024-04-25 | DAVIS D SCOTT Director | Grant or award · Deferred Share Units | +1,385.7 | 15,603.68 | ||
| 2024-04-25 | Beckerle Mary C Director | Grant or award · Deferred Share Units | +1,385.7 | 13,643.01 | ||
| 2024-04-25 | HEWSON MARILLYN A Director | Grant or award · Deferred Share Units | +1,385.7 | 10,173.44 | ||
| 2024-04-25 | Adamczyk Darius Director | Grant or award · Deferred Share Units | +1,385.7 | 3,712.7 |
Page 25 of 33 · 658 trades